



Bioorganic & Medicinal Chemistry

The International Journal for Research at the Interface
of Chemistry and Biology



Volume 11, Number 1
January 2003

Available online at
ScienceDirect

BIOORGANIC & MEDICINAL CHEMISTRY

Editor-in-Chief: **Professor Chi-Huey Wong**

Department of Chemistry, BCC 338, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
Facsimile: (1) 858 784 2409

American Regional Editor: Professor K. D. Janda, The Scripps Research Institute, Department of Chemistry, The Skaggs Institute for Chemical Biology, The Worm Institute of Research & Medicine, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
Facsimile: (1) 858 784 2595

Japanese Regional Editor: Professor Y. Hashimoto, Institute of Molecular & Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan
Facsimile: (81) 3 5841 8495

European Regional Editor: Professor H. Waldmann, Department of Chemical Biology, Max-Planck-Institut für Molekulare Physiologie, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany
Facsimile: (49) 231 133 2499

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: **Professor S. Neidle**

Professor D. L. Boger, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor S. G. Davies, Chemistry Research Laboratory, Department of Chemistry, University of Oxford, Mansfield Road, Oxford, OX1 3TA, UK

Professor B. Ganem, Department of Chemistry and Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853-1301, USA

Professor L. Ghosez, l'Institut Européen de Chimie et de Biologie (IECB) 33607 Pessac Cedex, France

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

Professor Y. Hashimoto, Institute of Molecular & Cellular Biosciences, The University of Tokyo, III-Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan

Professor T. Hayashi, Department of Chemistry, Faculty of Science, Kyoto University, Kyoto 606, Japan

Professor K. D. Janda, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor S. F. Martin, Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

Professor W. B. Motherwell, Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

Professor S. Neidle, The School of Pharmacy, Department of Pharmaceutical & Biological Chemistry, University of London, London WC1N 1AX, UK

Professor M. Shibasaki, Microbial Chemistry Research Center, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan

Professor R. J. K. Taylor, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK
(Associate Editors, Dr. P. A. O'Brien and Dr. D. K. Smith)

Professor E. J. Thomas, Department of Chemistry, University of Manchester, Brunswick Street, Manchester M13 9PL, UK
(Associate Editor, Professor J. A. Joule)

Professor K. Tomioka, Graduate School of Pharmaceutical Sciences, Department of Synthetic Medicinal Chemistry, Kyoto University, Kyoto 606-8501, Japan

Professor H. Waldmann, Max-Planck-Institut für Molekulare Physiologie, Department of Chemical Biology, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany

Professor C.-H. Wong, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor J. Wood, Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872

Professor Y. Yamamoto, Department of Chemistry, Faculty of Science, Tohoku University, Sendai 980-8578, Japan
(Associate Editor, Professor M. Hirama)

Professor S. Z. Zard, Laboratoire de Synthèse Organique, Ecole Polytechnique, F-91128, Cedex, France
(Associate Editor, Dr. B. Sire)

BOARD OF CONSULTING EDITORS

P. S. Anderson, Wilmington, DE

P. G. Baraldi, Ferrara

C. F. Barbas, III, La Jolla, CA

J. K. Barton, Pasadena, CA

C. Bertozzi, Berkeley, CA

B. S. J. Blagg, Lawrence, KS

J. Bode, ETH, Zurich

R. C. Breslow, New York, NY

T. C. Bruice, Santa Barbara, CA

A. R. Chamberlin, Irvine, CA

E. J. Corey, Cambridge, MA

B. F. Cravatt, La Jolla, CA

S. J. Danishefsky, New York, NY

P. B. Dervan, Pasadena, CA

A. Eschenmoser, Zürich

D. M. Floyd, Princeton, NJ

A. Giannis, Leipzig

B. Giese, Basel

P. Gmeiner, Erlangen

H. B. Gray, Pasadena, CA

G. L. Grunewald, Lawrence, KS

P. Herrling, Basel

D. Hilvert, Zürich

L. C. Hsieh-Wilson, Pasadena, CA

W. L. Jorgensen, New Haven, CT

J. A. Katzenellenbogen, Urbana, IL

J. Kelly, La Jolla, CA

P. Krosgaard-Larsen, Copenhagen

R. A. Lerner, La Jolla, CA

H. Liu, Austin, TX

L. A. Mitscher, Lawrence, KS

K. C. Nicolaou, La Jolla, CA

H. L. Pearce, Indianapolis, IN

C. D. Poulter, Salt Lake City, UT

J. Rebek, Jr, La Jolla, CA

B. Samuelsson, Stockholm

S. L. Schreiber, Cambridge, MA

P. G. Schultz, La Jolla, CA

P. Seeberger, Zürich

O. Seitz, Berlin

K. Shokat, San Francisco, CA

R. Silverman, Evanston, IL

J. Stubbe, Cambridge, MA

C. T. Supuran, Firenze

S. Walker, Cambridge, MA

C. T. Walsh, Boston, MA

P. A. Wender, Stanford, CA

G. Whitesides, Cambridge, MA

R. V. Woffenden, Chapel Hill, NC



Bioorganic & Medicinal Chemistry Volume 20, Issue 11, 2012


Contents

REVIEW

Recent developments and biological activities of thiazolidinone derivatives: A review

pp 3378–3395

Abhishek Kumar Jain, Ankur Vaidya, Veerasamy Ravichandran, Sushil Kumar Kashaw, Ram Kishore Agrawal*




ARTICLES

N⁴-Phenyl-substituted 2-acetylpyridine thiosemicarbazones: Cytotoxicity against human tumor cells, structure–activity relationship studies and investigation on the mechanism of action

pp 3396–3409


Marcella A. Soares, Josane A. Lessa, Isolda C. Mendes, Jeferson G. Da Silva, Raquel G. dos Santos, Lívia B. Salum, Hikmat Daghestani, Adriano D. Andricopulo, Billy W. Day, Andreas Vogt, Jorge L. Pesquero, Willian R. Rocha, Heloisa Beraldo*

Radiosynthesis of a ¹⁸F-labeled 2,3-diarylsubstituted indole via McMurry coupling for functional characterization of cyclooxygenase-2 (COX-2) in vitro and in vivo

pp 3410–3421

Torsten Knies*, Markus Laube, Ralf Bergmann, Fabian Sehn, Franziska Graf, Joerg Steinbach, Frank Wuest, Jens Pietzsch


The radiosynthesis of a 2,3-diarylsubstituted indole via McMurry cyclization as potential PET probe for functional characterization of cyclooxygenase-2 (COX-2) is described. The radiotracer was evaluated in vitro using COX-2 expressing tumor cell lines and in vivo by dynamic small animal PET studies on HT-29 tumor-bearing mice.



Syntheses and biological studies of novel spiro-piperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels–Alder reaction

pp 3422–3428


Cheng Ji, Weimin Lin, Garrett C. Moraski, Jane A. Thanassi, Michael J. Pucci, Scott G. Franzblau, Ute Möllmann, Marvin J. Miller*



Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists

pp 3429–3445


Maura Marinozzi*, Andrea Carotti, Emanuele Sansone, Antonio Macchiarulo, Emiliano Rosatelli, Roccaldo Sardella, Benedetto Natalini, Giovanni Rizzo, Luciano Adorini, Daniela Passeri, Francesca De Franco, Mark Pruzanski, Roberto Pellicciari



Free energy calculations on the binding of novel thiolactomycin derivatives to *E. coli* fatty acid synthase I

pp 3446–3453


Thomas Steinbrecher*, David A. Case, Andreas Labahn



Alstiphyllanines I–O, ajmaline type alkaloids from *Alstonia macrophylla* showing vasorelaxant activity

pp 3454–3459


Hiroko Arai, Kazumasa Zaima, Erika Mitsuta, Haruka Tamamoto, Aiko Saito, Yusuke Hirasawa, Abdul Rahman, Idha Kusumawati, Noor Cholies Zaini, Hiroshi Morita*



Bidirectional fluorescence properties of pyrene-based peroxisome proliferator-activated receptor (PPAR) α/δ dual agonist


pp 3460–3464

Shintaro Ban, Takuji Oyama, Jun-ichi Kasuga, Kenji Ohgane, Yoshino Nishio, Kosuke Morikawa, Yuichi Hashimoto, Hiroyuki Miyachi*

**Development of a new enzyme-responsive self-immolative spacer conjugate applicable to the controlled drug release**


pp 3465–3469

Hui-juan Jin*, Jing Lu, Xue Wu

**Synthesis and binding properties of new selective ligands for the nucleobase opposite the AP site**


pp 3470–3479

Yukiko Abe, Osamu Nakagawa, Rie Yamaguchi, Shigeki Sasaki*

**Synthesis of chalcone-amidobenzothiazole conjugates as antimitotic and apoptotic inducing agents**

pp 3480–3492


Ahmed Kamal*, Adla Mallareddy, Paidakula Suresh, Thokhir B. Shaik, V. Lakshma Nayak, Chandan Kishor, Rajesh V.C.R.N.C. Shetti, N. Sankara Rao, Jaki R. Tamboli, S. Ramakrishna, Anthony Addlagatta*



Hypnotic effects and GABAergic mechanism of licorice (*Glycyrrhiza glabra*) ethanol extract and its major flavonoid constituent glabrol pp 3493–3501


Suengmok Cho, Ji-Hae Park, Ae Nim Pae, Daeseok Han, Dongsoo Kim, Nam-Chul Cho, Kyoung Tai No, Hyejin Yang, Minseok Yoon, Changho Lee, Makoto Shimizu*, Nam-In Baek*

Licorice ethanol extract and its flavonoid-rich fraction and glabrol induce sleep via a positive allosteric modulation of GABA_A-BZD receptors. The binding affinity and pharmacophore model of glabrol and liquiritigenin indicate that the isoprenyl groups of glabrol may play a key role in binding to GABA_A-BZD receptors.



Synthesis and evaluation of γ -lactam analogs of PGE₂ as EP4 and EP2/EP4 agonists pp 3502–3522


Tohru Kambe*, Toru Maruyama, Yoshihiko Nakai, Hiroji Oida, Takayuki Maruyama, Nobutaka Abe, Akio Nishiura, Hisao Nakai, Masaaki Toda



EP4 subtype-selective agonists **3** and EP2/EP4 dual agonists **4** were optimized for their sustained release from PLGA microsphere formulation.

Activity landscape modeling of PPAR ligands with dual-activity difference maps pp 3523–3532

Oscar Méndez-Lucio, Jaime Pérez-Villanueva, Rafael Castillo*, José L. Medina-Franco*




A systematic characterization of the structure–activity relationships of diverse compounds with reported activity against PPAR α , PPAR δ , and PPAR γ .



Synthesis and cytotoxic activity of new acridine-thiazolidine derivatives pp 3533–3539


Francisco W. A. Barros, Teresinha Gonçalves Silva, Marina Galdino da Rocha Pitta, Daniel P. Bezerra, Letícia V. Costa-Lotufo, Manoel Odorico de Moraes, Cláudia Pessoa, Maria Aline F. B. de Moura, Fabiane C. de Abreu, Maria do Carmo Alves de Lima, Suely Lins Galdino, Ivan da Rocha Pitta*, Marília O. F. Goulart*



An unusually cold active nitroreductase for prodrug activations


pp 3540–3550

Ayhan Çelik*, Gülden Yetiş


**Synthesis, anticonvulsant activity, and neuropathic pain-attenuating activity of *N*-benzyl 2-amino-2-(hetero)aromatic acetamides**

pp 3551–3564





Pranjal K. Baruah, Jason Dinsmore, Amber M. King, Christophe Salomé, Marc De Ryck, Rafal Kaminski, Laurent Provins, Harold Kohn*



Ar = aromatic, heteroaromatic



Ar = aromatic, heteroaromatic


| Ar | FAA MES ED ₅₀ (mg/kg) | PAAD MES ED ₅₀ (mg/kg) | PAAD Formalin ED ₅₀ (mg/kg) |
|---|--|---|--|
|  | 11 | 100 (MAD) ^a | 33 |
|  | 15 | 85 | >160 |
|  | 10 | 85 | 29 |
|  | 12 | 67 | 45 |

^aMAD = minimal active dose

**Automated generation of turn mimetics: Proof of concept study for the MC4 receptor**

pp 3565–3574


J. Christian Baber, Richard Lowe, John Saunders, Miklos Feher*

**Synthesis and biological evaluation of a class of 5-benzylidene-2-phenyl-thiazolinones as potent 5-lipoxygenase inhibitors**


pp 3575–3583

Sebastian Barzen, Carmen B. Rödl, Andreas Lill, Dieter Steinhilber, Holger Stark*, Bettina Hofmann*

General structure:




Most active compound:



Simplified bicyclic pyridinol analogues protect mitochondrial function


pp 3584–3595

Xiaoqing Cai, Omar M. Khmour, Jennifer Jaruvangsanti, Sidney M. Hecht*

**Inverse Virtual Screening allows the discovery of the biological activity of natural compounds**


pp 3596–3602

Gianluigi Lauro, Milena Masullo, Sonia Piacente, Raffaele Riccio, Giuseppe Bifulco*

**A novel tetrahydrobenzoangelicin with dark and photo biological activity**


pp 3603–3608

Lisa Dalla Via*, Ornella Gia, Sergio Caffieri, Aída N. García-Argáez, Elías Quezada, Eugenio Uriarte

**Novel inhibitors of heat shock protein Hsp70-mediated luciferase refolding that bind to DnaJ**


pp 3609–3614

Joel A. Cassel*, Sergey Ilyin, Mark E. McDonnell, Allen B. Reitz

Compound **6**, butyl 3-[2-(2,4-dichlorophenoxy)acetamido]benzoate, binds to DnaJ and inhibits Hsp70/DnaJ protein refolding with an IC₅₀ value of 0.13 μM.

Synthesis, biological evaluation and molecular docking studies of novel 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone pp 3615–3621 derivatives


Li-Rong Zhang, Zhi-Jun Liu, Hui Zhang, Jian Sun, Yin Luo, Ting-Ting Zhao, Hai-Bin Gong*, Hai-Liang Zhu*



A series of new 2-(1,3,4-oxadiazol-2-ylthio)-1-phenylethanone derivatives (**6a–6x**) as potential focal adhesion kinase (FAK) inhibitors were synthesized. The bioassay tests demonstrated that compound **6i** showed the most potent activity, which inhibited the growth of MCF-7 and A431 cell lines with IC_{50} values of 0.14 and 0.01 μ M, respectively. Compound **6i** also exhibited significant FAK inhibitory activity ($IC_{50} = 0.02 \mu$ M). Docking simulation was performed to position compound **6i** into the active site of FAK to determine the probable binding model.


Discovery of novel indane derivatives as liver-selective thyroid hormone receptor β (TR β) agonists for the treatment of dyslipidemia pp 3622–3634

Hiroaki Shiohara*, Tetsuya Nakamura, Norihiko Kikuchi, Tomonaga Ozawa, Ryuichi Nagano, Akane Matsuzawa, Hideki Ohnata, Takahide Miyamoto, Kazuo Ichikawa, Kiyoshi Hashizume




Synthesis of methoxylated goniothalamin, aza-goniothalamin and γ -pyrones and their in vitro evaluation against human cancer cells pp 3635–3651

Rosimeire Coura Barcelos, Julio Cezar Pastre, Vanessa Caixeta, Débora Barbosa Vendramini-Costa, João Ernesto de Carvalho, Ronaldo Aloise Pilli*



Truncated phosphonated C-1'-branched N,O-nucleosides: A new class of antiviral agents pp 3652–3657


Roberto Romeo*, Caterina Carnovale, Salvatore V. Giofrè, Giovanni Romeo, Beatrice Macchi, Caterina Frezza, Francesca Marino-Merlo, Venerando Pistarà, Ugo Chiacchio



Lipophilic amines as potent inhibitors of *N*-acylethanolamine-hydrolyzing acid amidase


pp 3658–3665

Yumiko Yamano*, Kazuhito Tsuboi, Yuki Hozaki, Kiyohiro Takahashi, Xing-Hua Jin, Natsuo Ueda, Akimori Wada

**Cytotoxic heterocyclic triterpenoids derived from betulin and betulinic acid**


pp 3666–3674

Milan Urban, Martin Vlk, Petr Dzubak, Marian Hajduch, Jan Sarek*


**Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: Synthesis, anti-HCV and antitumor activity evaluations**

pp 3675–3685

Karlo Wittine, Maja Stipković Babić, Damjan Makuc, Janez Plavec, Sandra Kraljević Pavelić, Mirela Sedić, Krešimir Pavelić, Pieter Leysen, Johan Neyts, Jan Balzarini, Mladen Mintas*



*Corresponding author

+ Supplementary data available via SciVerse ScienceDirect

COVER

Dipyrone (metamizol) is a common antipyretic drug and the most popular non-opioid analgesic in many countries. In spite of its long and widespread use, molecular details of its fate in the body are not fully known. Two unknown metabolites were now found, viz. arachidonoyl amides, and positively tested for cannabis receptor binding (CB1 and CB2) and cyclooxygenase inhibition. Two more puzzle pieces of the dipyrone story found! (Rogosch, T.; Sinning, C.; Podlewski, A.; Watzer, B.; Schlosburg, J.; Lichtman, A.H.; Cascio, M.G.; Bisogno, T.; Di Marzo, V.; Nüsing, R.; Imming, P. *Bioorg. Med. Chem.* **2012**, *20*, 103–109.)

Available online at www.sciencedirect.com

SciVerse ScienceDirect

Indexed/Abstracted in: Beilstein, Biochemistry & Biophysics Citation Index, CANCERLIT, Chemical Abstracts, Chemistry Citation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica, MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE. Also covered in the abstract and citation database SciVerse Scopus®. Full text available on SciVerse ScienceDirect®



ELSEVIER

ISSN 0968-0896



Alstiphyllanines I–O, ajmaline type alkaloids from *Alstonia macrophylla* showing vasorelaxant activity

Hiroko Arai^a, Kazumasa Zaima^a, Erika Mitsuta^a, Haruka Tamamoto^a, Aiko Saito^a, Yusuke Hirasawa^a, Abdul Rahman^b, Idha Kusumawati^b, Noor Cholies Zaini^b, Hiroshi Morita^{a,*}

^a Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa, Tokyo 142-8501, Japan

^b Faculty of Pharmacy, Airlangga University, Jalan Dharmawangsa Dalam, Surabaya 60286, Indonesia

ARTICLE INFO

Article history:

Received 17 March 2012

Revised 4 April 2012

Accepted 6 April 2012

Available online 16 April 2012

Keywords:

Indole alkaloids

Alstonia macrophylla

Alstiphyllanines I–O

Ajmaline type alkaloids

Vasorelaxant activity

Nitric oxide

VDCs

ROCs

SAR

ABSTRACT

Seven new ajmaline type alkaloids, alstiphyllanines I–O (**1–7**) were isolated from the leaves of *Alstonia macrophylla* together with six related alkaloids (**8–13**). Structures and stereochemistry of **1–7** were fully elucidated and characterized by 2D NMR analysis. A series of alstiphyllanines I–O (**1–7**) as well as the known ajmaline type alkaloids (**8–13**) showed that they relaxed phenylephrine (PE)-induced contractions against rat aortic ring. Among them, vincamedine (**10**) showed potent vasorelaxant activity, which may be mediated through inhibition of Ca²⁺ influx through voltage-dependent Ca²⁺ channels (VDCs) and/or receptor-operated Ca²⁺ channels (ROCs) as well as partially mediated the NO release from endothelial cells. The presence of substituents at both N-1 and C-17 may be important to show vasorelaxation activity.

© 2012 Elsevier Ltd. All rights reserved.

1. Introduction

The vasodilators are useful for treatment of cerebral vasospasm and hypertension, and for improvement of peripheral circulation. Several endothelium-dependent vasodilators, such as bradykinin, acetylcholine, and histamine, have been reported to elevate Ca²⁺ levels in endothelial cells and activate NO release, leading to vasorelaxation.¹ On the other hand, contractile response in smooth muscle is caused by Ca²⁺ influx through VDCs and/or ROCs.² The endothelium-independent vasodilators, such as nifedipine, diltiazem, and verapamil, have been reported to inhibit VDCs and led to decrease the intracellular Ca²⁺ concentration in smooth muscle, leading to vasorelaxation.² K⁺ channels play important roles in the regulation of vascular tone.^{3–5} Indeed, the K⁺ channels present in blood vessels indirectly influence vascular tension by changing the resting membrane potential. Many vascularly active agents and drugs induce their vasodilator or vasoconstrictor effects by opening or closing K⁺ channels.⁶

Our screening study on vasodilators in traditional medicine⁷ discovered that the alkaloidal extract of *Alstonia macrophylla* shows remarkably vasodilation activity against rat aorta. The genus


Alstonia, which is widely distributed in tropical regions of Africa and Asia, are well-known rich sources of unique monoterpene indole alkaloids with various biological activities such as anticancer, antibacterial, anti-inflammatory, antitussive, and antimalarial properties.⁷ Recently, several new indole alkaloids were isolated from extracts of *Alstonia macrophylla* Wall. ex G. Don (Apocynaceae) collected in Indonesia.^{8,9} With an aim to isolate additional new alkaloids showing vasorelaxant activity, purification of extracts of *A. macrophylla* led to seven new alkaloids, alstiphyllanines I–O (**1–7**) together with six known alkaloids (**8–13**). Herein we report the isolation and structure elucidation of alstiphyllanines I–O (**1–7**) as well as vasorelaxant activity and structure–activity relationship (SAR) study of these ajmaline type indole alkaloids.

1.1. Structures of alstiphyllanines I–O (1–7)

Leaves of *A. macrophylla* were extracted with MeOH, and the extract was partitioned between EtOAc and 3% aqueous tartaric acid. Water-soluble materials, adjusted to pH 9 with satd aq Na₂CO₃, were extracted with CHCl₃. The CHCl₃-soluble materials were subjected to an LH-20 column (CHCl₃/MeOH, 1:1) followed by a silica gel column (CHCl₃/MeOH, 1:0–0:1). The eluted fractions were further separated by ODS HPLC (MeOH/H₂O/TFA) to afford **1** (5.6 mg, 0.0016% dry weight), **2** (12 mg, 0.0039%), **3** (1.5 mg, 0.0004%), **4**

* Corresponding author. Tel./fax: +81 3 5498 5778.

E-mail address: moritah@hoshi.ac.jp (H. Morita).



(15.2 mg, 0.0029%), **5** (7.2 mg, 0.0021%), **6** (1.5 mg, 0.0004%), and **7** (5.6 mg, 0.0016%), together with six known alkaloids, alstiphyllanine A (**8**),⁹ alstiphyllanine H (**9**),⁹ vincamedine (**10**),¹⁰ vincamajine (**11**),¹¹ vincamajine-17-*O*-veratrate (**12**),¹² and vincamajine-17-*O*-3',4',5'-trimethoxybenzoate (**13**).¹²

Alstiphyllanine I (**1**, [α]_D²⁶ −90 (c 1.0, MeOH)) showed the pseudomolecular ion peak at m/z 559 (M+H)⁺ in the ESIMS, and the molecular formula C₃₂H₃₄N₂O₇, was established by HRESIMS [m/z 559.2455 (M+H)⁺]. IR absorptions implied the presence of carbonyl (1750 and 1670 cm^{−1}) functionalities. The ¹H NMR data (Table 1) showed the presence of four aromatic protons, an ethylidene side chain, a methyl ester, and an acetyl group. The ¹³C NMR data (Table 2) revealed thirty-two carbon signals due to six sp² quaternary carbons, eight sp² methines, two ester carbonyls, one amide carbonyl, two sp³ quaternary carbons, five sp³ methines, three sp³ methylenes, and five methyl groups. Partial structures C-9 to C-12, C-5 to C-6, C-2 to C-15, and C-18 to C-19 were deduced from detailed analysis of the ¹H-¹H COSY spectrum of **1**. The HMBC cross-peaks of H₃-18 to C-20 and H-19 to C-21 placed the ethylidene side chain at C-20. The presence of veratroyl group (δ_C 56.5, 56.5, 112.9, 113.3, 124.1, 127.8, 150.7, and 154.6, respectively) and its connection to a nitrogen atom of the indole ring were elucidated by a HMBC correlation for H'-2 to C-23 (δ_C 170.6). The

HMBC correlations for H-17 to C-5 and C-6 and H-2 to C-17 indicated that **1** was an ajmaline-type alkaloid. The presence of an acetyl group was indicated by the HMBC correlations for H₃-25 and H-17 to C-24 (δ_C 169.9). Thus, **1** was an ajmaline-type alkaloid with a 3,4-dimethoxybenzoyl (veratroyl) group in place of a methyl group of vincamedine.¹⁰ The relative stereochemistry of **1** was elucidated by NOESY correlations as shown in computer-generated 3D drawing (Fig. 1). The NOESY correlations of H₃-18 to H-21 and H-19 to H-15 indicated that the ethylidene side chain was Z. In addition, H-3 correlated with both H-2 and H-14a, and H-14b with H-17 indicating that H-2 was α -oriented and H-17 was β -oriented.

Alstiphyllanine J (**2**, [α]_D²⁶ −94 (c 1.0, MeOH)) was revealed to have the molecular formula C₃₃H₃₆N₂O₈, by HRESITOFMS [m/z 589.2548 (M+H)⁺, Δ −0.2 mmu], which was larger than that of alstiphyllanine I (**1**) by CH₂O unit. Compared with ¹H NMR data of **1**, alstiphyllanine J was suggested to be an ajmaline-type backbone with an additional *O*-Me unit at C-5'. The HMBC cross-peak of H₃-*O*-Me (δ_H 3.85) to C-5' (δ_C 155.0) revealed the presence of an eudesmoyl moiety.

HRESITOFMS data [m/z 499.2220 (M+H)⁺, Δ −1.3 mmu] of alstiphyllanine K (**3**, [α]_D²⁶ −20 (c 1.0, MeOH)) established the molecular formula, C₃₀H₃₀N₂O₅, which was smaller than that of alstiphylla-

Table 1
¹H NMR data [δ_H (J, Hz)] of alstiphyllanines I–O (**1**–**7**)

| | 1 ^a | 2 ^a | 3 ^a | 4 ^a | 5 ^a | 6 ^a | 7 ^a |
|--------------------|----------------|----------------|----------------------|----------------------|-----------------------|----------------------|-----------------------|
| 2 | 4.38 (m) | 4.44 (m) | 4.34 (d, 4.8) | 4.30 (br s) | 4.35 (br s) | 4.29 (m) | 4.35 (br s) |
| 3 | 5.19 (m) | 5.19 (br s) | 4.87 (m) | 4.93 (m) | 5.09 (m) | 4.99 (m) | 5.09 (m) |
| 5 | 4.46 (m) | 4.44 (m) | 4.09 (m) | 4.11 (m) | 4.01 (m) | 4.15 (m) | 4.01 (m) |
| 6a | 2.22 (m) | 2.31 (d, 9.5) | 2.06 (d, 12.3) | 2.01 (d, 13.5) | 2.10 (dd, 12.4, 6.2) | 1.98 (m) | 2.10 (dd, 12.4, 6.2) |
| 6b | 2.87 (d, 11.0) | 2.86 (d, 9.5) | 2.79 (dd, 12.3, 3.6) | 2.86 (d, 13.5) | 2.91 (d, 12.4) | 2.88 (d, 11.0) | 2.91 (d, 12.4) |
| 9 | 7.25 (br s) | 7.23 (br s) | 7.22 (d, 6.6) | 7.29 (m) | 7.32 (m) | 7.32 (d, 6.9) | 7.32 (m) |
| 10 | 7.01 (br s) | 7.01 (m) | 6.98 (dd, 6.6, 7.8) | 7.00 (m) | 7.00 (m) | 7.01 (dd, 6.9, 8.7) | 7.00 (m) |
| 11 | 7.01 (br s) | 7.01 (m) | 6.93 (dd, 7.8, 7.8) | 6.98 (m) | 7.02 (m) | 6.93 (dd, 9.0, 8.7) | 7.02 (m) |
| 12 | 6.23 (br s) | 6.23 (m) | 6.22 (d, 7.8) | 6.27 (m) | 6.27 (m) | 6.11 (d, 9.0) | 6.27 (m) |
| 14a | 2.08 (t, 14.0) | 2.07 (t, 14.0) | 1.91 (m) | 1.85 (t, 13.9) | 1.95 (dd, 14.5, 12.4) | 1.91 (t, 14.3) | 1.95 (dd, 14.5, 12.4) |
| 14b | 2.61 (d, 14.0) | 2.59 (d, 14.0) | 2.53 (dd, 15.0, 6.0) | 2.49 (dt, 13.9, 7.1) | 2.55 (dt, 14.5, 4.9) | 2.49 (dd, 14.3, 5.0) | 2.55 (dt, 14.5, 4.9) |
| 15 | 3.39 (d, 3.6) | 3.37 (br s) | 3.24 (m) | 3.31 (m) | 3.37 (d, 3.6) | 3.33 (m) | 3.85 (m) |
| 17 | 6.02 (s) | 6.02 (s) | 5.96 (s) | 4.49 (s) | 4.52 (s) | 4.50 (s) | 4.56 (s) |
| 18 | 1.61 (d, 6.1) | 1.61 (d, 4.5) | 1.59 (d, 6.6) | 1.59 (d, 6.4) | 1.61 (d, 6.6) | 1.60 (d, 6.8) | 1.67 (d, 6.4) |
| 19 | 5.60 (m) | 5.59 (m) | 5.49 (m) | 5.50 (m) | 5.55 (m) | 5.55 (m) | 5.55 (m) |
| 21a | 4.37 (m) | 4.08 (m) | 3.84 (m) | 3.87 (m) | 4.01 (m) | 3.92 (m) | 4.03 (m) |
| 21b | 4.12 (d, 16.0) | 4.35 (d, 13.8) | 4.09 (m) | 4.11 (m) | 4.26 (m) | 4.18 (m) | 4.03 (m) |
| 25 | 1.91 (s) | 1.88 (s) | 1.90 (s) | | | | |
| CO ₂ Me | 3.78 (s) | 3.78 (s) | 3.76 (s) | 3.74 (s) | 3.76 (s) | 3.75 (s) | 3.76 (s) |
| 3'- <i>O</i> -Me | 3.78 (s) | 3.85 (s) | | 3.74 (s) | 3.81 (s) | | 3.81 (s) |
| 4'- <i>O</i> -Me | 3.92 (s) | 3.78 (s) | | 3.82 (s) | 3.87 (s) | | 3.87 (s) |
| 5'- <i>O</i> -Me | | 3.85 (s) | | | 3.81 (s) | | 3.81 (s) |
| 2' | 7.29 (s) | 7.05 (s) | 7.74 (d, 7.5) | 7.28 (m) | 7.01 (s) | 7.70 (m) | 7.01 (s) |
| 3' | | | 7.52 (dd, 7.6, 7.5) | | | 7.52 (m) | |
| 4' | | | 7.64 (dd, 7.6, 7.6) | | | 7.65 (t, 6.9) | |
| 5' | 7.06 (d, 6.9) | | 7.52 (dd, 7.6, 7.5) | 7.02 (d, 6.9) | | 7.52 (m) | |
| 6' | 7.41 (d, 6.9) | 7.05 (s) | 7.74 (d, 7.5) | 7.34 (d, 6.9) | 7.01 (s) | 7.70 (m) | 7.01 (s) |

^a TFA salt in CD₃OD.

Table 2
 ^{13}C NMR data (δ_{C}) of alstiphyllanines I–O (1–7)

| | 1 ^a | 2 ^a | 3 ^a | 4 ^a | 5 ^a | 6 ^a | 7 ^a |
|--------------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 2 | 68.3 | 68.3 | 69.0 | 69.2 | 69.1 | 69.4 | 69.1 |
| 3 | 57.0 | 57.1 | 55.9 | 56.4 | 57.7 | 56.8 | 57.7 |
| 5 | 64.7 | 64.8 | 63.8 | 63.9 | 64.1 | 64.6 | 64.1 |
| 6 | 34.3 | 34.2 | 35.7 | 34.6 | 34.5 | 34.9 | 34.5 |
| 7 | 56.6 | 57.0 | 57.5 | 57.7 | 57.7 | 57.9 | 57.7 |
| 8 | 129.6 | 129.6 | 130.9 | 130.7 | 131.4 | 131.7 | 131.4 |
| 9 | 125.2 | 125.1 | 125.2 | 127.0 | 127.1 | 127.2 | 127.1 |
| 10 | 124.9 | 125.0 | 124.7 | 124.5 | 124.8 | 124.7 | 124.8 |
| 11 | 129.8 | 129.7 | 129.4 | 128.9 | 129.1 | 129.0 | 129.1 |
| 12 | 117.0 | 117.1 | 116.9 | 116.2 | 116.3 | 116.4 | 116.3 |
| 13 | 145.4 | 145.3 | 145.5 | 145.4 | 145.1 | 145.0 | 145.1 |
| 14 | 22.4 | 22.6 | 25.5 | 22.0 | 21.9 | 22.8 | 21.9 |
| 15 | 36.6 | 36.7 | 35.7 | 36.7 | 36.5 | 36.5 | 30.1 |
| 16 | 60.3 | 61.3 | 60.7 | 61.3 | 61.4 | 61.9 | 61.4 |
| 17 | 74.9 | 74.9 | 76.1 | 75.5 | 75.6 | 75.6 | 75.5 |
| 18 | 12.9 | 12.8 | 12.6 | 12.7 | 12.7 | 12.7 | 13.1 |
| 19 | 123.7 | 123.8 | 121.2 | 121.8 | 122.3 | 121.9 | 122.3 |
| 20 | 128.9 | 128.7 | 129.8 | 131.6 | 129.6 | 131.3 | 129.6 |
| 21 | 52.2 | 52.3 | 52.7 | 52.5 | 52.5 | 52.5 | 55.1 |
| 22 | 169.8 | 170.8 | 171.9 | 172.2 | 172.0 | 172.3 | 172.0 |
| 23 | 170.6 | 170.5 | 171.9 | 171.7 | 171.5 | 172.1 | 171.5 |
| 24 | 169.9 | 169.8 | 170.3 | | | | |
| 25 | 20.5 | 20.4 | 20.6 | | | | |
| CO ₂ Me | 53.5 | 53.4 | 52.9 | 52.7 | 52.6 | 52.7 | 52.6 |
| 10-O-Me | | | | | | | |
| 3'-O-Me | 56.5 | 61.3 | | 56.9 | 57.1 | | 57.1 |
| 4'-O-Me | 56.5 | 57.0 | | 56.7 | 61.4 | | 61.4 |
| 5'-O-Me | | 61.3 | | | 57.1 | | 57.1 |
| N(1)-Me | | | | | | | |
| 1' | 127.8 | 130.5 | 136.6 | 128.7 | 131.5 | 136.6 | 131.5 |
| 2' | 113.3 | 107.8 | 129.8 | 113.7 | 108.0 | 129.6 | 108.0 |
| 3' | 150.7 | 155.0 | 130.1 | 150.9 | 155.1 | 130.2 | 155.1 |
| 4' | 154.6 | 143.4 | 133.5 | 154.6 | 143.6 | 133.6 | 143.6 |
| 5' | 112.9 | 155.0 | 130.1 | 112.7 | 155.1 | 130.2 | 155.1 |
| 6' | 124.1 | 107.8 | 129.8 | 124.0 | 108.0 | 129.6 | 108.0 |

^a TFA salt in CD₃OD.

nine I (**1**) by C₂H₄O₂ unit. The NMR data of **3** were analogous to those of **1** except for the following observation: two methoxy signals (δ_{H} 3.78 and 3.92) in **1** were lack in **3**. The presence of a benzoyl group was verified by the HMBC correlations of H-2' and H-6' to C-23.

Alstiphyllanine L (**4**, [α_{D}^{26} –68 (c 1.0, MeOH)]) was revealed to have the molecular formula C₃₀H₃₂N₂O₆, by HRESITOFMS [m/z 517.2347 (M+H)⁺, Δ +0.8 mmu], which was smaller than that of alstiphyllanine I (**1**) by an acetyl unit. IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.5) supported the presence of a hydroxyl group at C-17.

HRESITOFMS data [m/z 547.2429 (M+H)⁺, Δ –1.5 mmu] of alstiphyllanine M (**5**, [α_{D}^{26} –62 (c 1.0, MeOH)]) established the molecular

formula, C₃₁H₃₄N₂O₇, which was smaller than that of alstiphyllanine J (**2**) by an acetyl unit. IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.6) supported the presence of a hydroxyl group at C-17.

Alstiphyllanine N (**6**, [α_{D}^{26} –62 (c 1.0, MeOH)]) was revealed to have the molecular formula C₂₈H₂₈N₂O₄, by HRESITOFMS [m/z 457.2132 (M+H)⁺, Δ +0.5 mmu], which was smaller than that of alstiphyllanine K (**3**) by an acetyl unit. IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.6) supported the presence of a hydroxyl group at C-17.

Alstiphyllanine O (**7**, [α_{D}^{26} –53 (c 1.0, MeOH)]) had a molecular formula C₃₁H₃₄N₂O₇ based on the HRESITOFMS [m/z 547.2429 (M+H)⁺, Δ –1.5 mmu]. The IR absorption band at 3420 cm⁻¹ and ^{13}C chemical shift at C-17 (δ_{C} 75.5) supported the presence of a hydroxyl group at C-17. Analysis of the ¹H, ¹³C, and 2D NMR of **7** gave the same planar structure as **5**, suggesting that **7** should be a stereoisomer of **5**. The NOESY correlation of H-15/H₃-18 indicated that the ethylidene side chain was *E*.

A detail 2D NMR analysis of a series of alstiphyllanines J–O (**2**–**7**) suggested their structures were related ajmaline-type indole alkaloids. The relative stereochemistry of a series of alstiphyllanines J–O (**2**–**7**) was elucidated by NOESY correlations. The NOESY correlation of H₃-18 to H-21 and H-19 to H-15 indicated that the geometry of ethylidene side chain was *Z* except for that of alstiphyllanine O. The NOESY correlations of H-3/H-2 and H-14a and H-14b/H-17 indicated that H-2 was α -orientated and H-17 was β -oriented.

1.2. Vasorelaxant activity in ex-vivo

All isolated compounds except for **3** (it is not enough for evaluation because of the limited amount) were tested for vasorelaxant activity against rat aorta (Fig. 2). When PE (0.3 μM) was applied to thoracic aortic rings with endothelium after achieving a maximal response, a series of alstiphyllanines I, J, L–O (**1**, **2**, **4**–**7**) and their related ajmaline-type alkaloids, alstiphyllanine A (**8**), alstiphyllanine H (**9**), vincamedine (**10**), vincamajine (**11**), vincamajine-17-*O*-veratrate (**12**), and vincamajine-17-*O*-3',4',5'-trimethoxybenzoate (**13**), were added and some of them showed potent vasorelaxant effects at 30 μM (Fig. 2). The presence of a hydroxy group at C-17 and an *N*(4)-oxide reduced the potency of vasodilation. On the other hand, the presence of substituents at *N*(1) might affect slightly on vasorelaxation activity. In addition, compared with the geometry at C-19 of **5** and **7**, 19 Z might increase the potency of vasodilation.

Vincamedine (**10**) showed the excellent activity at early stage within 5–15 min after addition. Furthermore, to investigate the involvement of endothelial cells, vasorelaxant activity was tested using endothelium-denuded aorta (–EC rings) for **10** (Fig. 3).




Figure 1. Selected 2D NMR correlations for alstiphyllanine I (**1**).




Figure 2. Relaxation responses induced by isolated compounds (**1**, **2**, **4–13**) at 30 μM on the rat aortic rings precontracted with 0.3 μM phenylephrine. Values are the mean \pm S.D. ($n = 3$).




Figure 3. Concentration-dependent relaxation by **10** in +EC or –EC rings precontracted with PE (A). Vasorelaxant effect of **10** on +EC rings precontracted with PE in the presence or absence of L-NMMA (B). Values are the mean \pm S.E.M. ($n = 3$) * $P < 0.05$ and ** $P < 0.01$ respectively, versus +EC group.

Compound **10** caused concentration-response relaxation with maximum response at 100 μM in +EC rings (Fig. 3). The relaxation induced by **10** was partly attenuated in –EC rings and in the presence of N^{G} -monomethyl-L-arginine (L-NMMA, 100 μM), an inhibitor of nitric oxide synthase (NOS), suggesting that effects induced by **10** partially mediated the NO release from endothelial cells (Fig. 3). However, vasorelaxant effect of **10** on –EC rings still remained. Hence, subsequent investigations were focused on the direct effect of **10** on vascular smooth muscle cells using –EC rings.

To investigate the involvement of K^+ channel, the vasorelaxant effect of **10** in PE-contracted –EC rings was examined by pretreatment of tetraethylammonium chloride [TEA (nonselective large-conductance Ca^{2+} -activated K^+ channel (BK_{Ca}) inhibitor). The concentration-dependent response was not altered by TEA (Fig. 4), which suggested that vasorelaxant effect of **10** did not involve K^+ channel.

Cumulative addition of isotonic high- K^+ (10–80 mM) elicits a concentration-dependent contraction by Ca^{2+} influx via VDC. High K^+ -induced contractile response was significantly decreased by pretreatment of **10** (Fig. 5). Therefore, the relaxant effect of **10** was thought to be due to inhibitory effect on VDC-dependent Ca^{2+} influx.

In addition, we investigated the involvement of ROC. After pretreatment with PE and nicardipine in Ca^{2+} -free modified Krebs-Henseleit solution (KHS), the contractile response induced by CaCl_2 showed dose-dependent manner from 10 μM to 1 mM, presum-




Figure 4. Vasorelaxant effect of **10** on PE-precontracted –EC rings in the presence or absence of TEA. Values are the mean \pm S.E.M. ($n = 3$)




Figure 5. Concentration–response curves for isotonic high K^+ -induced contractions in $-EC$ rings in the presence or absence of **10**. Values are the mean \pm S.E.M. ($n = 3$) * $P < 0.05$ versus control group.




Figure 6. Effect of **10** on $CaCl_2$ -induced contraction of $-EC$ rings pretreated with PE and nifedipine in Ca^{2+} -free medium. Values are the mean \pm S.E.M. ($n = 3$) * $P < 0.05$, ** $P < 0.01$, and *** $P < 0.001$ respectively, versus control group.

ably due to the influx of Ca^{2+} via ROC. The addition of **10** significantly inhibited $CaCl_2$ -induced contraction dependent on ROC, suggesting that **10** also has inhibitory effect on Ca^{2+} influx via ROC (Fig. 6).

In conclusion, we isolated seven new ajmaline type alkaloids, alstiphyllanines I–O (**1**–**7**) from the leaves of *Alstonia macrophylla* together with six related alkaloids (**8**–**13**). Structures and stereochemistry of **1**–**7** were fully elucidated and characterized by 2D NMR analysis. A series of alstiphyllanines I–O (**1**–**7**) as well as the known ajmaline type alkaloids (**8**–**13**) showed that they relaxed PE-induced contractions against rat aortic ring. The presence of a hydroxy group at C-17 and an *N*(4)-oxide reduced the potency of vasodilation. On the other hand, the presence of substituents at *N*(1) and the geometry at C-19 might affect slightly on vasorelaxation activity. Among them, vincamedine (**10**) showed potent vasorelaxant activity, which may be mediated through inhibition of Ca^{2+} influx through VDCs and/or ROCs as well as partially mediated the NO release from endothelial cells.

2. Experimental section

2.1. General methods

1H and 2D NMR spectra were recorded on a Bruker AV 400 spectrometer and chemical shifts were reported using residual CD_3OD (δ_H 3.31 and δ_C 49.0) as internal standards. Standard pulse sequences were employed for the 2D NMR experiments. 1H – 1H COSY, HOHAHA, and NOESY spectra were measured with spectral widths

of both dimensions of 4800 Hz, and 32 scans with two dummy scans were accumulated into 1 K data points for each of 256 t_1 increments. NOESY spectra in the phase sensitive mode were measured with a mixing time of 800 ms. For HMQC spectra in the phase sensitive mode and HMBC spectra, a total of 256 increments of 1 K data points were collected. For HMBC spectra with Z-axis PFG, a 50 ms delay time was used for long-range C–H coupling. Zero-filling to 1 K for F_1 and multiplication with squared cosine-bell windows shifted in both dimensions were performed prior to 2D Fourier transformation.

2.2. Material

The leaves of *Alstonia macrophylla* were collected at Ngliyep, East Java, Indonesia in 2008. The botanical identification was made by Ms. Sri Wuryanti, Purwodadi Botanical Garden, Indonesia. A voucher specimen has been deposited in the herbarium at Purwodadi Botanical Garden, Pasuruan, Indonesia.

2.3. Extraction and isolation

The leaves of *A. macrophylla* (900 g) were extracted with MeOH to give the extract (154 g). The MeOH extract (59 g) was treated with 3% tartaric acid (pH 2) and then partitioned with EtOAc. The aqueous layer was treated with satd aq Na_2CO_3 aq to pH 9 and extracted with $CHCl_3$ to give alkaloidal fraction (2.0 g). The alkaloidal fraction was purified by LH-20 column ($CHCl_3/MeOH$, 1:0) and SiO_2 column ($CHCl_3/MeOH$, 1:0 \rightarrow 0:1) and the fractions eluted by $CHCl_3/MeOH$ (50:1 to 20:1) were purified by ODS HPLC (59–61% MeOH with 0.1% CF_3CO_2H ; flow rate, 2 mL/min; UV detection at 254 nm) to afford alstiphyllanines I (**1**, 5.6 mg, 0.0016% dry weight), J (**2**, 12 mg, 0.0039%), K (**3**, 1.5 mg, 0.0004%), L (**4**, 15.2 mg, 0.0029%), M (**5**, 7.2 mg, 0.0021%), N (**6**, 1.5 mg, 0.0004%), and O (**7**, 1.5 mg, 0.0004%), together with six known alkaloids, alstiphyllanine A (**8**),⁹ alstiphyllanine H (**9**),⁹ vincamedine (**10**),¹⁰ vincamajine (**11**),¹¹ vincamajine-17-*O*-veratrate (**12**),¹² and vincamajine-17-*O*-3',4',5'-trimethoxybenzoate (**13**).¹²

2.3.1. Alstiphyllanine I (1)

Brown amorphous solid; $[\alpha]_D^{26} -90$ (c 1.0, MeOH); IR (film) ν_{max} 1750 and 1670 cm^{-1} ; UV (MeOH) λ_{max} 297 (ϵ 9600), 276 (11,300), 217 (24,700) and 202 (30,900) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 559 (M+H)⁺; HRESITOFMS m/z 559.2455 [(M+H)⁺, $\Delta +1.1$ mmu, calcd for $C_{32}H_{35}N_2O_7$, 559.2444].

2.3.2. Alstiphyllanine J (2)

Brown amorphous solid; $[\alpha]_D^{26} -94$ (c 1.0, MeOH); IR (film) ν_{max} 1750 and 1680 cm^{-1} ; UV (MeOH) λ_{max} 293 (ϵ 9600), 277 (ϵ 35,800), 219 (5000), and 201 (10,600) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 589 (M+H)⁺; HRESITOFMS m/z 589.2548 [(M+H)⁺, $\Delta -0.2$ mmu, calcd for $C_{33}H_{37}N_2O_8$, 589.2550].

2.3.3. Alstiphyllanine K (3)

Brown amorphous solid; $[\alpha]_D^{26} -20$ (c 1.0, MeOH); IR (film) ν_{max} 1750 and 1680 cm^{-1} ; UV (MeOH) λ_{max} 293 (ϵ 1900), 268 (2400), 219 (5000) and 201 (10,600) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 499 (M+H)⁺; HRESITOFMS m/z 499.2220 [(M+H)⁺, $\Delta -1.3$ mmu, calcd for $C_{30}H_{31}N_2O_5$, 499.2233].

2.3.4. Alstiphyllanine L (4)

Brown amorphous solid; $[\alpha]_D^{26} -68$ (c 1.0, MeOH); IR (film) ν_{max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{max} 286 (ϵ 8400), 273 (9200), 220 (21,700) and 202 (37,300) nm; 1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 517 (M+H)⁺; HRESITOFMS m/z 517.2347 [(M+H)⁺, $\Delta +0.8$ mmu, calcd for $C_{30}H_{33}N_2O_6$, 517.2339].

2.3.5. Alstiphyllanine M (5)

Brown amorphous solid; $[\alpha]_D^{26} -62$ (c 1.0, MeOH); IR (film) ν_{\max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{\max} 293 (ϵ 9200), 273 (15,000), 213 (41,100) and 202 (62,500) nm; ^1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 547 (M+H) $^+$; HRESITOFMS m/z 547.2429 [(M+H) $^+$, $\Delta -1.5$ mmu, calcd for $\text{C}_{31}\text{H}_{35}\text{N}_2\text{O}_7$, 547.2444].

2.3.6. Alstiphyllanine N (6)

Brown amorphous solid; $[\alpha]_D^{26} -62$ (c 1.0, MeOH); IR (film) ν_{\max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{\max} 291 (ϵ 6300), 271 (8800), 218 (11,100) and 202 (49,100) nm; ^1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 457 (M+H) $^+$; HRESITOFMS m/z 457.2132 [(M+H) $^+$, $\Delta +0.5$ mmu, calcd for $\text{C}_{28}\text{H}_{29}\text{N}_2\text{O}_4$, 457.2127].

2.3.7. Alstiphyllanine O (7)

Brown amorphous solid; $[\alpha]_D^{26} -53$ (c 1.0, MeOH); IR (film) ν_{\max} 3420, 1730, and 1670 cm^{-1} ; UV (MeOH) λ_{\max} 293 (ϵ 9200), 271 (15,000), 218 (41,100) and 202 (62,500) nm; ^1H and ^{13}C NMR data (Tables 1 and 2); ESIMS m/z 547 (M+H) $^+$; HRESITOFMS m/z 547.2429 [(M+H) $^+$, $\Delta -1.5$ mmu, calcd for $\text{C}_{31}\text{H}_{35}\text{N}_2\text{O}_7$, 547.2444].

2.4. Vasodilation assay¹³

The thoracic aorta between the aortic arch and the diaphragm was harvested from a male Wistar rat weighting 260 g and placed in oxygenated, modified KHS (118.0 mM NaCl, 4.7 mM KCl, 25.0 mM NaHCO_3 , 1.8 mM CaCl_2 , 1.2 mM NaH_2PO_4 , 1.2 mM MgSO_4 , and 11.0 mM glucose). After removing loosely adhering fat and connective tissue, the aorta was cut into ring preparations 3 mm in length. The aorta was placed in bath filled well-oxygenated (95% O_2 , 5% CO_2) KHS at 37 °C with connection to a force-displacement transducer (Nihon Kohden, TB-611T, Tokyo, Japan). The aorta ring was equilibrated for 60 min under a resting tension of 1.0 g.

After equilibration, each aorta ring was contracted by treatment with PE (0.3 μM). Aortic rings with 80% relaxation by acetylcholine (ACh, 10 μM) were regarded as endothelium-intact aorta (+EC rings). Following washout, these rings were contracted once again with the same concentration of PE. When the PE-induced contraction reached a plateau, each sample (30 μM) or ACh (1 nM–10 μM) was added cumulatively. IC_{50} of ACh (positive control) was approximately 1 μM in this experimental system.

To test for the involvement of endothelium-dependency in relaxation response, the endothelial cells were removed by rubbing and were confirmed by observing the loss of ACh-induced relaxation (–EC rings). When PE-induced contractions reached a plateau, vincamedine (**10**) was added cumulatively.

To test for the involvement of K^+ channel, TEA (1 mM; nonselective large-conductance Ca^{2+} -activated K^+ channel (BK_{Ca}) inhibitor) was applied to the aortic rings 30 min prior to precontraction by PE. Cumulative concentration-response of **10** was compared with or without TEA.

To investigate the involvement of VDC in the vasorelaxant response by **10**, aortic rings were equilibrated in KHS for 60 min. Ca^{2+} -free high K^+ solution (10–80 mM as KCl) was then added for observation of contractile response (control). When maximum contraction was achieved, the ring was washed and equilibrated for 60 min. After pretreatment of **10** at 30 μM for 30 min, Ca^{2+} -free high K^+ solution was added once again. A KCl-induced contractile response with or without each sample was compared.

To clarify the involvement of ROC-dependent Ca^{2+} influx, a contractile response induced by Ca^{2+} was recorded twice. Firstly, aortic rings were equilibrated in Ca^{2+} -free KHS with 0.01 mM EGTA for 60 min. After pretreatment with nicardipine (1 μM) for 30 min and following PE-prestimulation, aorta ring was contracted by cumulative addition of CaCl_2 (10 μM –1 mM). After the confirmation of maximum contraction, the ring was washed and equili-

brated for 60 min to carry out second contractile experiment. Vincamedine (**10**) was added before PE-stimulation, and Ca^{2+} -induced contractile response was recorded as same as first contractile experiment. These two contractile responses by Ca^{2+} with/without **10** were evaluated.

All tested compounds were dissolved in DMSO and diluted with saline. The final concentration of DMSO in the organ bath was less than 0.1%, and did not show any effects on contraction or relaxation. All other drugs were dissolved in saline.

All results are expressed as means \pm S.E.M. Statistical analysis was done by Student's paired or unpaired *t*-test. $P < 0.05$ was considered statistically significant.

These animal experimental studies were conducted in accordance with the Guiding Principles for the Care and Use of Laboratory Animals, Hoshi University and under the supervision of the Committee on Animal Research of Hoshi University, which is accredited by the Ministry of Education, Science, Sports Culture, and Technology of Japan.

Acknowledgements

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and a Grant from The Open Research Center Project in Hoshi University.

References and notes

- Muller, J. M.; Davis, M. J.; Kuo, L.; Chilian, W. M. *Am. J. Physiol.* **1999**, 276, H1706–H1714; Muller, B.; Kleschyov, A. V.; Gyorgy, K.; Stoclet, J. C. *Physiol. Res.* **2000**, 49, 19–26.
- Karaki, H.; Ozaki, H.; Hori, M.; Mitsui-Saito, M.; Amano, K.; Harada, K.; Miyamoto, S.; Nakazawa, H.; Won, K. J.; Sato, K. *Pharmacol. Rev.* **1997**, 49, 157.
- Faraci, F. M.; Heistad, D. D. *Physiol. Rev.* **1998**, 78, 53–97.
- Standen, N. B.; Quayle, J. M. *Acta Physiol. Scand.* **1998**, 164, 549–577.
- Tanaka, Y.; Koike, K.; Toro, L. J. *Smooth Muscle Res.* **2004**, 40, 125–153.
- Shieh, C. C.; Coghlan, M.; Sullivan, J. P.; Gopalakrishnan, M. *Pharmacol. Rev.* **2000**, 52, 557–594.
- Morita, H.; Iizuka, T.; Choo, C. Y.; Chan, K. L.; Itokawa, H.; Takeya, K. *J. Nat. Prod.* **2005**, 68, 1686; Morita, H.; Eda, M.; Iizuka, T.; Hirasawa, Y.; Sekiguchi, M.; Yun, Y. S.; Itokawa, H.; Takeya, K. *Bioorg. Med. Chem. Lett.* **2006**, 17, 4458–4461; Morita, H.; Enomoto, M.; Hirasawa, Y.; Iizuka, T.; Ogawa, K.; Kawahara, N.; Goda, Y.; Matsumoto, T.; Takeya, K. *Bioorg. Med. Chem. Lett.* **2007**, 17, 5410–5413; Morita, H.; Tomizawa, Y.; Deguchi, J.; Ishikawa, T.; Arai, H.; Zaima, K.; Hosoya, T.; Hirasawa, Y.; Matsumoto, T.; Kamata, K.; Ekasari, W.; Widyawaruyanti, A.; Wahyuni, T. S.; Zaini, N. C.; Honda, T. *Bioorg. Med. Chem.* **2009**, 17, 8234–8240; Hirasawa, Y.; Hara, M.; Nugroho, A. E.; Sugai, M.; Zaima, K.; Kawahara, N.; Goda, Y.; Awang, K.; Hadi, A. H. A.; Morita, H. *J. Org. Chem.* **2010**, 75, 4218–4223; Matsumoto, T.; Kobayashi, T.; Ishida, K.; Hirasawa, Y.; Morita, H.; Honda, T.; Kamata, K. *Bio. Pharm. Bull.* **2010**, 33, 844–848; Matsuo, H.; Okamoto, R.; Zaima, K.; Hirasawa, Y.; Ismail, I. S.; Lajis, N. H.; Morita, H. *Bioorg. Med. Chem.* **2011**, 19, 4075–4079; Zaima, K.; Takeyama, Y.; Koga, I.; Saito, A.; Tamamoto, H.; Azziz, S. S. A.; Mukhtar, M. R.; Awang, K.; Hadi, A. H. A.; Morita, H. *J. Nat. Med.*, in press; Zaima, K.; Deguchi, J.; Matsuno, Y.; Kaneda, T.; Hirasawa, Y.; Morita, H. *J. Nat. Med.*, in press; Zaima, K.; Koga, I.; Iwasawa, N.; Hosoya, T.; Hirasawa, Y.; Kaneda, T.; Ismail, I. S.; Lajis, N. H.; Morita, H. *J. Nat. Med.*, in press.
- (a) Kamarajan, P.; Sekar, N.; Mathuram, V.; Govindasamy, S. *Biochem. Int.* **1991**, 25, 491–498; (b) Saraswathi, V.; Subramanian, S.; Ramamoorthi, N.; Mathuram, V.; Govindasamy, S. *Med. Sci. Res.* **1997**, 25, 167–170; (c) Keawpradub, N.; Kirby, G. C.; Steele, J. C. P.; Houghton, P. J. *Planta Med.* **1999**, 65, 690–694; (d) Husain, K.; Jantan, I.; Kamaruddin, N.; Said, I. M.; Aimi, N.; Takayama, H. *Phytochemistry* **2001**, 57, 603–606; (e) Husain, K.; Jantan, I.; Said, I. M.; Aimi, N.; Takayama, H. *J. Asian Nat. Prod. Res.* **2003**, 5, 63–67; (f) Jagetia, G. C.; Baliga, M. S. *Phytother Res.* **2006**, 20, 103–109; (g) Khan, M. R.; Omoloso, A. D.; Kihara, M. *Fitoterapia* **2003**, 74, 736–740; (h) Gupta, R. S.; Bhatnager, A. K.; Joshi, Y. C.; Sharma, M. C.; Khushalani, V.; Kachhawa, J. B. *Pharmacology* **2005**, 75, 57–62.
- Hirasawa, Y.; Arai, H.; Zaima, K.; Ohtarina, R.; Rahman, A.; Ekasari, W.; Indrayanto, G.; Zaini, N.; Morita, H. *J. Nat. Prod.* **2009**, 72, 304–307; Arai, H.; Hirasawa, Y.; Rahman, A.; Ekasari, W.; Zaini, N.; Sato, S.; Aoyama, C.; Takeo, J.; Morita, H. *Bioorg. Med. Chem.* **2010**, 18, 2152–2158.
- Caron, C.; Yachouli, Y.; Massiot, G.; Men-Olivier, L.; Pusset, J.; Sevenet, T. *Phytochemistry* **1984**, 23, 2355–2357.
- Ratnayake, C.; Arambewela, L.; Silva, K.; Rahman, A.; Alvi, K. *Phytochemistry* **1975**, 14, 1849–1854.
- Abe, F.; Yamauchi, T.; Santisuk, T. *Phytochemistry* **1994**, 37, 249–252.
- Morita, H.; Iizuka, T.; Choo, C. Y.; Chan, K. L.; Takeya, K.; Kobayashi, J. *Bioorg. Med. Chem. Lett.* **2006**, 16, 4609–4611.

Source details

Feedback > Compare sources >

Bioorganic and Medicinal Chemistry

Scopus coverage years: from 1993 to Present

Publisher: Elsevier

ISSN: 0968-0896 E-ISSN: 1464-3391

Subject area: [Pharmacology, Toxicology and Pharmaceutics: Pharmaceutical Science](#) [Chemistry: Organic Chemistry](#)
[Biochemistry, Genetics and Molecular Biology: Clinical Biochemistry](#) [Pharmacology, Toxicology and Pharmaceutics: Drug Discovery](#) [View all](#)

Source type: Journal

[View all documents >](#)

[Set document alert](#)

[Save to source list](#)

[Source Homepage](#)

CiteScore 2019

5.5



SJR 2019

0.739



SNIP 2019

0.940



Bioorganic and Medicinal Chemistry

COUNTRY

United Kingdom



Universities and research institutions in United Kingdom

SUBJECT AREA AND CATEGORY

Biochemistry, Genetics and Molecular Biology

- Biochemistry
- Clinical Biochemistry
- Molecular Biology
- Molecular Medicine

Chemistry

- Organic Chemistry

Pharmacology, Toxicology and Pharmaceutics

- Drug Discovery
- Pharmaceutical Science

PUBLISHER

Elsevier Ltd.

H-INDEX

154

PUBLICATION TYPE

Journals

ISSN

14643391, 09680896

COVERAGE

1993-2020

INFORMATION

[Homepage](#)









[How to publish in this journal](#)

[Contact](#)

SCOPE

Bioorganic & Medicinal Chemistry publishes complete accounts of research of outstanding significance and timeliness on all aspects of molecular interactions at the interface of chemistry and biology, together with critical review articles. The journal publishes reports of experimental results in medicinal chemistry, chemical biology and drug discovery and design, emphasizing new and emerging advances and concepts in these fields. The aim of the journal is to promote a better understanding at the molecular level of life processes, and living organisms, as well as the interaction of these with chemical agents. The Journal welcomes papers on: the medicinal chemistry and associated biology (including target identification and validation) of established or new disease targets- the reporting of the discovery, design or optimization of potent new compounds or biological agents- the analysis and discussion of structure-activity relationships and pharmacological issues relevant to drug design and action using in vitro and in vivo models, including the use of computational techniques when closely linked to experimental data- the reporting of "first-in-class" new therapeutic compounds- the chemical biology or bioorganic/bioinorganic chemistry that significantly advances knowledge of a biological mechanism- methodological advances that are chemistry-based and which significantly impact on medicine or biology- the preparation and examination of biotherapeutics for the treatment of pathophysiological disease states- the development of materials for specific therapeutic targeting

Quartiles



Bioorganic and Medicinal Chemistry

Pharmaceutical Science

Q1

SJR 2019 0.74

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

``